AA
ITRM

Ancora Advisors’s Iterum Therapeutics ITRM Stock Holding History

Ancora Advisors’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-38
Closed -$59 – 1882
2024
Q1 		$59 Hold
38
– – ﹤0.01% 1786
2023
Q4 		$75 Hold
38
– – ﹤0.01% 1711
2023
Q3 		$30 Hold
38
– – ﹤0.01% 1757
2023
Q2 		$41 Hold
38
– – ﹤0.01% 1770
2023
Q1 		$38 Hold
38
– – ﹤0.01% 1926
2022
Q4 		$0 Hold
38
– – ﹤0.01% 1874
2022
Q3 		$0 Sell
38
-1
-3% -$3 ﹤0.01% 2106
2022
Q2 		$0 Hold
39
– – ﹤0.01% 2286
2022
Q1 		$0 Hold
39
– – ﹤0.01% 2467
2021
Q4 		$0 Hold
39
– – ﹤0.01% 2410
2021
Q3 		$0 Hold
39
– – ﹤0.01% 2253
2021
Q2 		$1K Buy
+39
New +$846 ﹤0.01% 1889

Other funds holding ITRM

AF
Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
KFS
Kelly Financial Services Braintree, Massachusetts $467M AUM 21.13% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BBPWM
Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return

Ancora Advisors's ITRM Position: Q2 2024 in Review

Ancora Advisors sold out of Iterum Therapeutics (ITRM) in Q2 2024, closing a stake of 38 shares — an estimated $59 sold.

Ancora Advisors first reported a position in ITRM in Q2 2021 and held it in 12 quarters. The position peaked at $1K in Q2 2021. 15 funds tracked by Wall St. Rank hold ITRM as of Q2 2024.

  • Ancora Advisors reported no remaining Iterum Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Ancora Advisors sold 38 Iterum Therapeutics shares in Q2 2024, an estimated $59.
  • Ancora Advisors first reported a position in Iterum Therapeutics in Q2 2021 and held it in 12 quarters.
  • Ancora Advisors's Iterum Therapeutics position peaked at $1K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2024.

Based on Ancora Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.